Human Tissue and Sample Acquistion

人体组织和样本采集

• 批准号: 8576984
• 负责人: Donna L. Farber
• 金额: $ 25.68万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-06-01 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8576984
• 关键词: Biopsy; Biopsy Specimen; Blood specimen; Bone Marrow; Cells; Clinical Management; Collaborations; Consent; Enrollment; Goals; Human; Human Resources; Immune response; Immunology; Institutional Review Boards; Instruction; Intestines; Laboratories; Life; Lung; Lymphocyte; Lymphoid Cell; Lymphoid Tissue; Mucous Membrane; New York; Organ Donor; Organ Transplantation; Patients; Peripheral; Population; Process; Protocols documentation; Research; Research Personnel; Resources; Sampling; Services; Source; Spleen; Surgeon; Suspension substance; Suspensions; T-Lymphocyte; Tissue Sample; Tissues; Transplant Recipients; Transplantation; Work; base; biobank; human tissue; lymph nodes; novel; peripheral blood; programs

The main goal of this program is to conduct a novel analysis of lymphocyte and innate lymphoid cell populations in human lymphoid and mucosal tissues in steady state and in organ transplantation, to elucidate novel aspects of human immune responses in the whole body that have not previously been explored. We will use two sources of human tissues for this program: deceased organ donors and transplant patients. Projects 1-3 will examine T, B and innate lymphoid cells (ILC) in multiple tissues obtained from . organ donors, and Project 4 will characterize lymphocyte and ILC populations in intestinal transplants. For all of the projects, the acquisition of human tissues is essential. The human tissue and sample acquisition core will be responsible for coordinating all ofthe personnel, institutional assurance, protocols and MTAs necessary to acquire and process human tissues, and distribute samples to all four projects. This core will function for all years of the project as it is essential to the entire program. This essential core will be divided into two parts based on the two main sources of human tissue samples. In the first part, the core will obtain and process multiple lymphoid and mucosal tissues from human organ donors. We have established the necessary protocols and collaborations with CUMC surgeons and the New York Organ Donor network (NYODN) to obtain from research-consented organ donors, tissues that are not used for life-saving transplantation. For this part of the core, we will coordinate the acquisition of multiple lymphoid tissues and mucosal tissues from organ donors whose next-of-kin have consented for use of tissues for research. The tissues will be processed in the laboratory and cell suspensions, whole tissues and tissue mounts will be distributed to all project laboratories (Projects 1-4). For the second part ofthe core, we will coordinate the acquisition of biopsy and peripheral blood samples from transplant patients. We will obtain biopsy and peripheral blood specimens from intestinal transplant patients who will be enrolled in studies related to Project 4. The personnel in this core will maintain IRB protocols for obtaining samples, enroll patients in this study, will work with the clinicians to obtain biopsy and blood samples as part of their clinical management, coordinate their distribution to Project 4 investigators for the characterization of T cell reconstitufion and alloreactivity, and to the CCTI Biobank for processing and storage.

该项目的主要目标是对稳态和器官移植中的人类淋巴和粘膜组织中的淋巴细胞和固有淋巴样细胞群进行新的分析，以阐明人类全身免疫反应的新方面，这些方面以前从未被探索过。我们将在这个项目中使用两个人体组织来源：已故的器官捐赠者和移植患者。项目1-3将检查从多个组织中获得的T、B和固有淋巴样细胞(ILC)。项目4将描述肠道移植中淋巴细胞和ILC群体的特征。对于所有的项目来说，获取人体组织是必不可少的。人体组织和样本采集核心将负责协调采集和处理人体组织所需的所有人员、机构保证、协议和MTA，并将样本分发给所有四个项目。这一核心将在项目的所有年份发挥作用，因为它对整个计划至关重要。根据人体组织样本的两个主要来源，这一基本核心将分为两个部分。在第一部分中，核心将从人体器官捐赠者那里获得和处理多个淋巴和粘膜组织。我们已经与CUMC外科医生和纽约器官捐赠者网络(NYODN)建立了必要的协议和合作，以从研究同意的器官捐赠者那里获得不用于挽救生命的移植的组织。对于核心的这一部分，我们将协调从器官捐赠者那里获取多种淋巴组织和粘膜组织，这些器官捐赠者的近亲已同意使用组织进行研究。这些组织将在实验室进行加工，细胞悬浮液、整个组织和组织贴片将分发给所有项目实验室(项目1-4)。对于核心的第二部分，我们将协调从移植患者身上获取活检和外周血样本。我们将从将参加项目4相关研究的肠移植患者那里获取活检和外周血液样本。这一核心的人员将维持获取样本的IRB协议，招募患者参加这项研究，将与临床医生合作获得活检和血液样本，作为其临床管理的一部分，协调它们的分配给项目4研究人员以确定T细胞重构和同种异体反应的特征，并将其分配到CCTI生物库进行处理和存储。